ClinicalTrials.gg
CompletedNCT06209424BTLPUpdated Nov 18, 2026

Modified Breath Test to Determine Anabolic Sensitivity Across Physical Activity States

An interventional study of Habitual Activity and Step-Reduction in Resistance Exercise, Physical Inactivity and Amino Acids, sponsored by University of Toronto. Completed at 1 site in Canada. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Toronto · Not applicable, Interventional, and Other

How we know

Updated Nov 18, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Sedentary Behavior with a site in Canada — 18 open to participants now, 19 under way, none of them phase 3. Sedentary Behavior · Canada.

Enrollment
59th of 69
16 · median 50
Started
2024
with 4 others
No phase
67 of 73
18 open now
Registered
59th of 73
by date
Lead sponsor
9 of 73
University of Toronto

Among the 73 studies in Sedentary Behavior with a site in Canada, this one is the 59th largest by enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2024, is one of 67 with no phase, and was the 59th registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

18 of the 73 studies in Sedentary Behavior with a site in Canada are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Sedentary Behavior with a site in Canada, or all of them as a file.
02

Study summary

Developing tools to detect when our bodies are more resistant towards protein synthesis is valuable for identification of when someone may be at risk of losing body or muscle mass such as with aging or certain diseases. The current study aims to refine our previous breath test method to be more effective at measuring changes in how the body processes protein in different situations, such as resting, reducing physical activity, and doing resistance exercise. We hypothesize that using a lower amount of dietary amino acids in our breath test will be effective at detecting lower amounts of amino acids used after exercise, and a greater amount with step reduction compared to normal activity levels

Read the detailed description

Maintaining high-quality and abundant lean body mass (LBM) is crucial for growth, health, and performance across all ages, sexes, and activity levels. Body protein, including skeletal muscle, undergoes constant turnover, breaking down old and damaged proteins and using dietary amino acids (AA) to synthesize new proteins, especially after resistance exercise. Unused AA are oxidized for energy and excreted as carbon dioxide (CO2). Studying the proportion of AA used for protein synthesis versus energy production provides insights into acute growth of LBM after a meal in different physiological states (e.g., at rest or exercise). Stable isotope tracers, commonly administered intravenously, are used in protein metabolism research to examine the effects of nutrition and exercise on protein turnover. However, this method may not be feasible for vulnerable populations.

While exercise has been shown to enhance anabolic sensitivity (i.e., greater utilization of dietary AA for protein synthesis), step-reduction leads to fed-state anabolic resistance (I.e., reduced utilization of dietary AA for protein synthesis). Indeed, reduced habitual activity, whether mild or severe, leads to fed-state anabolic resistance, reducing the muscle protein synthesis (MPS) response to amino acids. For instance, one week of reduced daily steps (\~1,192 steps/day) decreased MPS rates by approximately 27% in young males who habitually reach \~10,000 steps/day, i.e., a \~75% reduction from habitual.

Therefore, developing metabolic tools to detect anabolic resistance before muscle mass loss occurs would be valuable for both treatment and prevention of age-related muscle loss. Recently, our laboratory demonstrated the effectiveness of a non-invasive stable isotope "breath test" to detect increased anabolic sensitivity in males after resistance exercise. This study, in addition to ongoing metabolic trials in our lab, utilized a protein dose of 0.25g/kg which has been shown to maximize the rate of myofibrillar protein synthesis and to support whole-body protein synthesis. However, this dose may not adequately distinguish between more subtle changes in anabolic sensitivity. Further, a lower protein dose may reduce the duration for which breath samples would need to be collected, which would minimize participant burden and time commitment going forward.

Therefore, the present project will use previously established 'breath test' methodology but with a lower protein dose to assess the following objectives:

  1. To investigate whether the 'optimized' non-invasive breath test can detect changes in anabolic sensitivity (i.e., leucine oxidation) across varying physiological states (I.e., rest, step-reduction, whole-body resistance exercise) after feeding, in young healthy adults.
  2. To assess the reproducibility, and day-to-day variability of our breath test during habitual activity in both an at-home and a controlled laboratory setting
03

Conditions studied

  • Resistance Exercise
  • Physical Inactivity
  • Amino Acids
  • Dietary Protein

Browse trials for

Keywords

  • Sex
  • Step-Reduction
  • Habitual Activity
  • Protein Metabolism
  • Resistance Exercise
  • Stable Isotopes
  • Anabolic Sensitivity
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy young (age: 18-35 years)
  • between normal to overweight (18.5-29.9 kg/m2)
  • if oral (OC) user, must be on monophasic OCs for at least 3 months prior to study
  • if non-OC user, then must have regular menstrual cycles (length: 25-35 days) for at least 3 months prior to study and at least 6 months off of OCs

Exclusion criteria

Exclusion Criteria:

  • Chronic disease diagnosis (cardiovascular, thyroid, diabetes)
  • Current or recent remission of cancer
  • Regular use of NSAID (except low-dose aspirin), anticoagulants
  • Use of prescription drugs that would impact muscle protein synthesis (e.g., Statins, Lithium, ADHD medication, etc..)
  • Insertion of intrauterine device (IUD) - exception: copper
  • Smoking
  • Use of illicit drugs (growth hormones, testosterone)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    In-Person Phase

    Habitual Activity + Resistance Exercise Metabolic Trials

    Behavioral: Habitual Activity · Behavioral: Resistance Exercise

  • Active comparator
    At-Home Phase

    Habitual Activity + Step-Reduction Metabolic Trials

    Behavioral: Habitual Activity · Behavioral: Step-Reduction

Interventions

  • BehavioralHabitual Activity

    Participants will maintain habitual levels of physical activity (inclusive of structured physical activity).

    Also known as: Free-Living Activity

  • BehavioralStep-Reduction

    Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.

    Also known as: Reduced Physical Activity

  • BehavioralResistance Exercise

    Participants will undergo a 50-minute resistance exercise protocol, which includes multiple sets of different exercises using weights. Each set will consist of 10 repetitions at 75% of their 1 repetition maximum (1RM). The exercises include bench press superset with lat pulldowns, overhead press superset with seated cable rows, leg press, and leg extensions with 90s rest in between sets. Before the exercise protocol, there will be a standardized 10-minute warm-up that involves cycling, leg swings, arm circles, bodyweight squats, and bench push-ups

    Also known as: Full-Body Resistance Exercise

06

What researchers measure

Primary outcomes

  1. Exogenous Leucine Oxidation (umol/kg)

    Exogenous Leucine Oxidation determined from breath 13CCO2 enrichment. Breath samples will be collected every 20-30min after test drink ingestion to determine breath 13CO2 enrichment. Total leucine oxidation will be determined from the area under the 13CO2 enrichment by time curve.

    Time frame: 5 hours

  2. Net Leucine Retention (umol/kg)

    Whole-Body Net Leucine Retention determined from the difference between exogenous leucine oxidation and leucine ingestion the 6 hour measurement period.

    Time frame: 5 hours

Other outcomes

  1. Feeling and Felt Arousal (Likert Scale)

    Feeling and felt arousal will be assessed 3-times a day in conjunction with mealtimes (i.e., breakfast, lunch, dinner) to understand whether acute periods of inactivity are sufficient to induce changes in activation and arousal states in otherwise healthy active individuals

    Time frame: 6 days (during at-home phase)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Dec 2025, 23 months.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 23 months is above that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2024 → Dec 2025 and completion Apr 2025 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Jan 17, 2024
StartActual
Jan 15, 2024
Primary completionActual
Dec 31, 2025was Dec 2024
CompletionActual
Dec 31, 2025was Apr 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Primary completion
Dec 31, 2024→Dec 31, 2025 (actual)
Nov 18, 2026
Study completion
Apr 30, 2025→Dec 31, 2025 (actual)
Nov 18, 2026
Enrollment
12 (estimated)→16 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2024→Dec 31, 2025 (now actual)
    Study completion Apr 30, 2025→Dec 31, 2025 (now actual)
    Enrollment 12 (estimated)→16 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06209424
Responsible party
Daniel Moore (Principal Investigator, University of Toronto) — Principal investigator
First posted
Jan 17, 2024
Start date
Jan 15, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Nov 18, 2026

Study contacts

Ines Kortebi, MSc
study director · University of Toronto
Hugo JW Fung, PhD (c)
study chair · University of Toronto
Daniel R Moore, PhD
principal investigator · University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion